Gryphon has a set of protein engineering technologies for creating even very large synthetic proteins, useful for modifying existing protein therapeutics to improve them as drugs, creating multivalent artificial therapeutics and vaccines, and doing rapid structure-function analysis of newly uncovered proteins.
You may also be interested in...
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.
The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.